IgA-Mediated Killing of Tumor Cells by Neutrophils Is Enhanced by CD47-SIRP alpha Checkpoint Inhibition

摘要

Therapeutic monoclonal antibodies (mAb), directed toward either tumor antigens or inhibitory checkpoints on immune cells, are effective in cancer therapy. Increasing evidence suggests that the therapeutic efficacy of these tumor antigen-targeting mAbs is mediated-at least partially-by myeloid effector cells, which are controlled by the innate immune-checkpoint interaction between CD47 and SIRP alpha. We and others have previously demonstrated that inhibiting CD47-SIRP alpha interactions can substantially potentiate antibody-dependent cellular phagocytosis and cytotoxicity of tumor cells by IgG antibodies both in vivo and in vitro. IgA antibodies are superior in killing cancer cells by neutrophils compared with IgG antibodies with the same variable regions, but the impact of CD47-SIRP alpha on IgA-mediated killing has not been investigated. Here, we show that checkpoint inhibition of CD47 - SIRP alpha interactions further enhances destruction of IgA antibody-opsonized cancer cells by human neutrophils. This was shown for multiple tumor types and IgA antibodies against different antigens, i.e., HER2/neu and EGFR. Consequently, combining IgA antibodies against HER2/neu or EGFR with SIRP alpha inhibition proved to be effective in eradicating cancer cells in vivo. In a syngeneic in vivo model, the eradication of cancer cells was predominantly mediated by granulocytes, which were actively recruited to the tumor site by SIRP alpha blockade. We conclude that IgA-mediated tumor cell destruction can be further enhanced by CD47-SIRP alpha checkpoint inhibition. These findings provide a basis for targeting CD47-SIRP alpha interactions in combination with IgA therapeutic antibodies to improve their potential clinical efficacy in tumor patients.